# US 2018/0021446 A1 · Systems for stabilizing and delivering active agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021446 A1
- Document ID: US20180021446A1
- Status: Published application
- Kind: A1
- Application number: 15/446,212
- Filed: 2017-03-01
- Published: 2018-01-25
- Earliest claimed: 2014-08-14
- Assignees: Mamoun M. Alhamadsheh
- Inventors: MAMOUN ALHAMADSHEH; MIKI S. PARK; WILLIAM K. CHAN; XIAOLING LI; SRAVAN C. PENCHALA; MARK R. MILLER
- Web page: https://patentgrep.com/patent/US20180021446A1

## CPC

- A61K 47/54: the modifying agent being an organic compound
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 5/02: of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P 9/12: Antihypertensives
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A delivery system for an active agent, comprising:
a ligand that is selective for transthyretin in the serum of a subject; and,
a linker configured for operatively attaching the ligand covalently to an active agent, wherein the linker ranges from 14-20 angstroms in length;
wherein the system has a structure comprising:
where,
n is 1 to 8;
R1 and R3 are independently selected from a short chain alkyl having 1 to 4 carbon atoms;
R2 is selected from the group consisting of a hydrogen, a short chain alkyl having 1 to 4 carbon atoms, and an aryl;
Xa is C(R4)(R5), O, N—R5, or S; where R4 and R5 are independently selected from hydrogen, an alkyl having 1 to 4 carbon atoms, a substituted alkyl, an alkoxy, hydroxyl, an alkoxycarbonyl, an an amino;
Ra is CHO, COOH, COOCH3, COOR6, CONR7R8, tetrazolyl, CONHOH, B(OH)2, CONHSO2Ar, CONHCH(R9)COOH, CF3, hydrogen, halogen, alkyl, substituted alkyl, acyl, substituted acyl, carboxyl, heterocyclic group, sulfonamide, sulfonyl fluoride, thioester, alkoxycarbonyl or substituted alkoxycarbonyl;
Rb is the linker and is positioned ortho or meta to Ra, the linker including a CHO, COOH, COOCH3, COOR6, CONR7R8, tetrazolyl, CONHOH, B(OH)2, CONHSO2Ar, CONHCH(R9)COOH, CF3, hydrogen, halogen, alkyl, substituted alkyl, acyl, substituted acyl, carboxyl, heterocyclic group, sulfonamide, sulfonyl fluoride, ester, thioester, ether, thioether, triazolyl, alkoxycarbonyl or substituted alkoxycarbonyl;
R6 is alkyl, haloalkyl, cycloalkyl, or heterocyclyl;
R7 and R8 are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl; and,
R9 is the side chain of a naturally occurring α-amino carboxylic acid;
or, a pharmaceutically acceptable salt, ester, enol ether, enol ester, amide, acetal, ketal, orthoester, hemiacetal, hemiketal, hydrate, solvate or prodrug thereof.

### Claim 23 (depends on 22)

The delivery system of claim 22, wherein the ligand has the structure of Compound (VIIIc):
or, a pharmaceutically acceptable salt, ester, enol ether, enol ester, acetal, amide, ketal, orthoester, hemiacetal, hemiketal, hydrate, solvate or prodrug thereof; and,
the linker is attached to the ligand ortho at C15 to the carboxyl group at C14.

### Claim 24 (depends on 22)

The delivery system of claim 22, wherein the ligand has the structure of Compound (VIIIc):
or, a pharmaceutically acceptable salt, ester, enol ether, enol ester, acetal, amide, ketal, orthoester, hemiacetal, hemiketal, hydrate, solvate or prodrug thereof; and,
the linker is attached to the ligand meta at C16 to the carboxy carbon at C14.

### Claim 25 (depends on 23)

A method of increasing the in vivo half-life of an active agent, the method comprising covalently attaching the delivery system of claim 23 to an active agent, the active agent comprising a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an oligosaccharide, an imaging agent, and combinations thereof.

### Claim 26 (depends on 24)

A method of increasing the in vivo half-life of an active agent, the method comprising covalently attaching the delivery system of claim 24 to an active agent, the active agent comprising a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an oligosaccharide, an imaging agent, and combinations thereof.

### Claim 27 (depends on 22)

A method of increasing the in vivo half-life of an active agent in blood serum, the method comprising covalently attaching the delivery system of claim 22 to an active agent, the active agent comprising a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an oligosaccharide, an imaging agent, and combinations thereof.

### Claim 28 (depends on 24)

A method of increasing the in vivo half-life of an active agent in blood serum, the method comprising covalently attaching the delivery system of claim 24 to a drug, the active agent comprising a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an oligosaccharide, an imaging agent, and combinations thereof.

### Claim 29 (depends on 23)

A method of increasing the in vivo half-life of an active agent in the blood serum, the method comprising covalently attaching the delivery system of claim 23 to an active agent; wherein, the active agent comprises a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an oligosaccharide, an imaging agent, and combinations thereof.

### Claim 30 (depends on 24)

A method of increasing the in vivo half-life of an active agent in blood serum, the method comprising covalently attaching the delivery system of claim 24 to an active agent; wherein, the active agent comprises a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an oligosaccharide, an imaging agent, and combinations thereof.

### Claim 31 (depends on 22)

A method of reducing the immunogenicity of an active agent in vivo, the method comprising:
obtaining a delivery system of claim 22;
covalently attaching the delivery system to an active agent to create a conjugated active agent, the active agent comprising a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an imaging agent, and combinations thereof;
wherein, the transthyretin shields the active agent from antibody generation in vivo.

### Claim 32 (depends on 24, 31)

The method of claim 31, wherein the obtaining comprises obtaining the delivery system of claim 24.

### Claim 33 (depends on 23, 31)

The method of claim 31, wherein the obtaining comprises obtaining the delivery system of claim 23.

### Claim 34 (depends on 22)

The delivery system of claim 22, wherein the linker, Rb, attaches (i) to the ligand through an ether bond and (ii) to the active agent through an amide bond.

### Claim 35 (depends on 22)

The delivery system of claim 22, wherein
the linker, Rb, attaches (i) to the ligand through an ether bond and (ii) to the active agent through an ester;

### Claim 36 (depends on 22)

The delivery system of claim 22, wherein
the linker, Rb, attaches (i) to the ligand through an ether bond and (ii) to the active agent through an amide bond or an ester bond;
Ra is a carboxy group;
R1 is a methyl group;
R2 is hydrogen;
R3 is a methyl group; and,
the active agent is a protein or peptide.

### Claim 37 (depends on 22)

A method of administering an active agent to a subject, the method comprising:
covalently attaching the delivery system of claim 22 to an active agent to create a conjugated active agent comprising a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an oligosaccharide, an imaging agent, and combinations thereof; and,
administering the conjugated active agent to the subject.

### Claim 38 (depends on 23)

A method of administering an active agent to a subject, the method comprising:
covalently attaching the delivery system of claim 23 to a drug to create a conjugated active agent comprising a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an oligosaccharide, an imaging agent, and combinations thereof; and,
administering the conjugated active agent to the subject.

### Claim 39 (depends on 24)

A method of administering an active agent to a subject, the method comprising:
covalently attaching the delivery system of claim 24 to a drug to create a conjugated active agent comprising a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an oligosaccharide, an imaging agent, and combinations thereof; and,
administering the conjugated active agent to the subject.
